Floatz logo

Metformin

Frailty

VA Office of Research and DevelopmentSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Frailty cohort.

Asset / SponsorPhaseRating
Mitoquinone mesilate
UConn Health
Phase 2CCC
Tesamorelin
Massachusetts General Hospital
Phase 2CCC
METAMIZOLE
University of Oviedo
N/AD
NEPENTHE
University of Oviedo
N/AD
Edoxaban
Brigham and Women's Hospital
D

View all 10 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →